Study of ELA026 for secondary HLH
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an investigational drug, ELA026, for people with secondary hemophagocytic lymphohistiocytosis (sHLH), a rare condition where the immune system becomes overactive and damages organs. The study aims to see if ELA026 can calm the immune system and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 6 years old (some groups require being 12 or older).
- You must have been diagnosed with secondary HLH, based on meeting at least 5 out of 8 standard criteria.
- You must not have had previous treatment for primary HLH (a genetic form).
- You must not have an unknown trigger for your sHLH, except in certain cases.
- You must not have had a stem cell transplant within the last 100 days (or 30 days for a specific part).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial looks for a DNA marker in people with HLH caused by lymphoma. It may help doctors better confirm the cause of HLH and guide treatment decisions.
Hear when a new Secondary Hemophagocytic Lymphohistiocytosis (sHLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.